Position of the Transparency Council – Opdivo (nivolumab)
At its meeting on 5 May 2025, the Transparency Council adopted position No. 50/2025 on the assessment of the drug Opdivo (nivolumab) under the drug program “Treatment of patients with urothelial cancer (ICD-10: C61, C65, C66, C67, C68)”.